The New Year does not seem to prove anything special for pharmaceutical companies. According to the news published in Business Standard, the expectations of the price fall in the US market are expected to be due to the results of Indian generic drug manufacturers
Afterwards, we have got weak. This clearly means that pharmaceutical companies are still not getting good days. Sales of Taro Pharma, American subsidiary of Lupine, Dr Reddy's, Glenmark and Sun Pharma in the US, have dropped by 40 percent, so that their consolidated performance has been affected.
Taro also has a decline in sales growth. For whom TARO chief executive Uday Bolldota said that the American generic market is constantly facing challenging pricing environment and competitive pressure. Israeli company Teva is the world's largest generic manufacturer. Teva has also expressed the possibility of weakening it in 2018 as compared to the previous estimates after the disappointing performance of the December quarter.
It is being told that in the next two years, the market will increase by 50 percent in the approval of new products, increasing the consolidation between buyers and offering opportunities for new competitors to present their products. Due to the two-digit price decline, American generic sales will lead to a decline of 4-5 percent on an annual basis during the next three years.
Afterwards, we have got weak. This clearly means that pharmaceutical companies are still not getting good days. Sales of Taro Pharma, American subsidiary of Lupine, Dr Reddy's, Glenmark and Sun Pharma in the US, have dropped by 40 percent, so that their consolidated performance has been affected.
Taro also has a decline in sales growth. For whom TARO chief executive Uday Bolldota said that the American generic market is constantly facing challenging pricing environment and competitive pressure. Israeli company Teva is the world's largest generic manufacturer. Teva has also expressed the possibility of weakening it in 2018 as compared to the previous estimates after the disappointing performance of the December quarter.
It is being told that in the next two years, the market will increase by 50 percent in the approval of new products, increasing the consolidation between buyers and offering opportunities for new competitors to present their products. Due to the two-digit price decline, American generic sales will lead to a decline of 4-5 percent on an annual basis during the next three years.